Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA announces positive phase 3 results for Toujeo


Saturday, 14 Jun 2014 01:01pm EDT 

Sanofi SA:Says that, in a pooled analysis, investigational therapy Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia).At any time of day, including night-time events, compared with Lantus(R) (insulin glargine [rDNA origin] injection, 100 U/mL).Pooled analysis comprised data from three differing type 2 patient populations.In this analysis, more pronounced, significant reductions in low blood sugar rates at any time of day, including nighttime, were observed with Toujeo during the 8-week titration period when compared with Lantus. 

Company Quote

91.2
 --
30 Apr 2015